TTIL Trial on Alzheimer’s Aggression and Agitation Treatment Now Fully Enrolled

TTIL Trial on Alzheimer’s Aggression and Agitation Treatment Now Fully Enrolled
The Irish subsidiary of biopharmaceutical company Transition Therapeutics Inc. has finished patient enrollment for its phase 2 clinical study to assess a novel therapy for mild, moderate and severe Alzheimer’s disease. Transition Therapeutics Ireland Limited (TTIL) will now evaluate the neuropsychiatric drug candidate ELND005, expecting it to reduce both agitation and aggression. TTIL is going to conduct the phase

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *